Therapeutics

Nektar pulls NDA for pain drug after unanimous AdComm rejection

2 days ago   |   Fierce Biotech

Nektar Therapeutics has withdrawn the new drug application for its opioid oxycodegol after an advisory committee unanimously recommended against approval. The 27-0 vote against...
Read more ...

Associate or Sr. Associate Scientist - Phanes Therapeutics Inc - San Diego, CA

2 days ago   |   San Diego Biotechnology   |   3 articles

Our mission is to become a source ofinnovation for the biotech and pharma industry. Phanes Therapeutics, Inc.is a biotech company focused on the discovery and...From Phanes...
Read more ...

Research Assistant - Phanes Therapeutics Inc - San Diego, CA

2 days ago   |   San Diego Biotechnology   |   3 articles

Is a biotech company focused on discovery and. We believe that innovative thinking, seamless execution, team. The candidate will have opportunities to learn and...From Phanes...
Read more ...

Mirati Therapeutics: Clinical Trial Associate

2 days ago   |   San Diego Biotechnology   |   3 articles

Mirati Therapeutics: We are seeking a highly motivated individual to join Mirati Therapeutics as a Clinical Trial Associate within the Clinical Science/Operation Tea San Diego...
Read more ...

IT Manager - Mirati Therapeutics Inc - San Diego, CA

2 days ago   |   San Diego Biotechnology   |   3 articles

The ideal candidate will possess a mix of excellent leadership, technical skills, and an inclination to deliver the best user experience possible.From Mirati Therapeutics Inc...
Read more ...

IT Manager - Mirati Therapeutics Inc - San Diego, CA

2 days ago   |   San Diego Biotechnology   |   4 articles

The ideal candidate will possess a mix of excellent leadership, technical skills, and an inclination to deliver the best user experience possible.From Mirati Therapeutics Inc...
Read more ...

FDA Panel Votes Down Nektar Opioid Painkiller, Asks for More Data

FDA Panel Votes Down Nektar Opioid Painkiller, Asks for More Data

2 days ago   |   Xconomy

As the nation grapples with the ongoing opioid crisis, an FDA advisory panel on Tuesday unanimously voted against recommending approval of a Nektar Therapeutics painkiller that...
Read more ...

Clinical Trial Associate - Mirati Therapeutics Inc - San Diego, CA

2 days ago   |   San Diego Biotechnology   |   4 articles

Comfortable in a fast-paced small biotech company environment and able to adjust workload based on changing priorities.From Mirati Therapeutics Inc - Wed, 15 Jan 2020 01:15:02...
Read more ...

Senior Sourcing Manager - Poseida Therapeutics Inc - San Diego, CA

2 days ago   |   San Diego Biotechnology   |   3 articles

Develop and manage sourcing implementation plans, market & spend analysis, eRFX development & execution, competitive bidding, negotiations, contracts, and...From Poseida...
Read more ...

Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

2 days ago   |   San Diego Biotechnology

SAN DIEGO, Jan. 14, 2020 /PRNewswire/ - Mirati Therapeutics, Inc. today announced the closing of its previously announced underwritten public offering of 3,538,462 shares of...
Read more ...


Register you to post on BioTech Mag

Free Registration

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Bio Roundup: EQRx's Ambitions, Nektar No Vote, New Frazier Fund & More

Bio Roundup: EQRx's Ambitions, Nektar No Vote, New Frazier Fund & More

Perhaps the most talked-about news at the JP Morgan Healthcare Conference this week was a new startup that launched with $200 million and an ambitious claim its first drug... Read more ...

Trending News on Crop Biotech in 2019

Trending News on Crop Biotech in 2019

We summarized the top 10 most trending Crop Biotech Update news shared on social media to give you a glimpse of crop biotech happenings in 2019. Read on and make sure you don't... Read more ...

Cancer Drug Developer BioNTech to Buy Neon Therapeutics in $67M Deal

Cancer Drug Developer BioNTech to Buy Neon Therapeutics in $67M Deal

Neon Therapeutics closed 2019 by curtailing its cancer vaccine programs and laying off 24 percent of its workforce, part of a corporate restructuring aimed at finding a new... Read more ...

Event Announcement: Xcelerating Life Sciences San Diego

Event Announcement: Xcelerating Life Sciences San Diego

We're excited to announce the first in Xconomy's new Xcelerating Life Sciences event series convening local communities of innovators, executives, rising pioneers... Read more ...

Mayo Clinic Joins $60M Financing for Biomedical Software Firm nference

Mayo Clinic Joins $60M Financing for Biomedical Software Firm nference

Startup nference has closed a $60 million Series B financing round to expand the use of its augmented intelligence platform in clinical research and drug development. Mayo... Read more ...

How Breast Cancer Reunited Six High School Friends

How Breast Cancer Reunited Six High School Friends

Four of the six of us from my high school inner circle have had breast cancer over the past two years. And that has me wondering. Did a shared environmental exposure, stamped... Read more ...

Stepping into their own

Stepping into their own

Two Bond Life Sciences Center researchers find their path in teaching and research Sarah Unruh and Vinit Shanbhag have both taken paths that have led them toward teaching... Read more ...

Emendo Biotherapeutics Nabs $61M for “Next-Generation CRISPR” R&D

Emendo Biotherapeutics Nabs $61M for “Next-Generation CRISPR” R&D

Emendo Biotherapeutics, a company aiming to apply CRISPR gene editing to a wider range of genetic diseases, has raised $61 million in financing. The Series B round was led by... Read more ...

103395 Biorepository Assistant

CANCER CENTER/ Solid Tumor Therapeutics Salary commensurate with qualifications and experienceFiling Deadline: Fri 1/31/2020... Read more ...

Quantitative visualization of subcellular lignocellulose revealing the...

As a renewable carbon source, biomass energy not only helps in resolving the management problems of lignocellulosic wastes, but also helps to alleviate the global climate... Read more ...